Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Lunai Bioworks Inc LNAI

Healthcare Biotechnology
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors;... see more

Current News (NDAQ:LNAI)

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Canadian Press, with file by Stockhouse April 15, 2026

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

PR Newswire December 9, 2025

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

PR Newswire November 25, 2025

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

PR Newswire November 5, 2025

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

ACCESS Newswire October 30, 2025

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

ACCESS Newswire October 16, 2025

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

ACCESS Newswire October 16, 2025

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

ACCESS Newswire October 6, 2025
View More News ››

Opinion & Analysis (NDAQ:LNAI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LNAI)

looks like a roll back

pure earnings, pumping the stock to get it back to $1. I think they are in trouble.
Bullhunk - March 20, 2026

Pump and dump

be careful these guys are on there last hurra. Broke looking to dump
Bullhunk - March 17, 2026
View more Bullboard ››

Birchtech Corp.

Birchtech Corp.

Birchtech Corp., an environmental services and technology company, engages in developing and delivering solutions to the ...
View More »

Podcasts